Beam Therapeutics (BEAM) Cash from Operations (2019 - 2026)

Beam Therapeutics (BEAM) has 8 years of Cash from Operations data on file, last reported at 128513000.0 in Q1 2026.

• On a quarterly basis, Cash from Operations fell 23.71% year-over-year to 128513000.0 in Q1 2026; TTM through Mar 2026 was 369731000.0, a 5.22% decrease from a year earlier, with the FY2025 full-year figure at 345102000.0, up 0.62% from the prior year.
• Cash from Operations for Q1 2026 stood at 128513000.0, down from 83289000.0 in the prior quarter.
• Over the last five years, Cash from Operations for BEAM reached as high as 218490000.0 in Q1 2022 and fell as low as 128513000.0 in Q1 2026.
• Historically, Cash from Operations has averaged 55737000.0 across 5 years, with a median of 83009000.0 in 2024.
• On a YoY basis, Cash from Operations climbed as much as 666.36% in 2022 and fell as far as 3880.93% in 2022.
• Year by year, Cash from Operations stood at 69191000.0 in 2022, then soared by 295.22% to 135073000.0 in 2023, then slumped by 156.54% to 76365000.0 in 2024, then fell by 9.07% to 83289000.0 in 2025, then tumbled by 54.3% to 128513000.0 in 2026.
• Per Business Quant data, the three most recent Cash from Operations figures were 128513000.0 in Q1 2026, 83289000.0 in Q4 2025, and 81479000.0 in Q3 2025.